Key Takeaways
- 37 deep-tech ventures from BRICS nations presented at the expo, spanning AI cancer screening, space technology and carbon capture.
- AI cancer screening tools were the most health-relevant showcase, aimed at faster, cheaper detection of breast, cervical and oral cancers.
- India’s own cervical cancer push — over 80 lakh HPV vaccinations so far — shows the gap between lab-stage AI and ground-level delivery.
- Rural and district-level health infrastructure, not Delhi’s expo floor, will decide whether AI cancer screening ever reaches ordinary patients.
What Exactly Was Showcased at the BRICS Deep-Tech Expo?
The expo brought together 37 ventures from across BRICS member states — India, China, Russia, Brazil, South Africa and newer entrants like the UAE and Egypt — under one roof to pitch what organisers called “frontier technology for the Global South.” The three clusters getting the most attention were AI-driven diagnostics, space and satellite tech, and carbon capture systems.
It’s an odd mix on paper. But the logic is straightforward: these are the categories where BRICS nations argue they no longer need to import solutions from Silicon Valley or Europe. Health tech, and specifically AI cancer screening, was positioned as the most immediately useful of the three — the one with a clear patient at the other end of it.
Who Were the Ventures Behind the AI Cancer Screening Tools?
Details on individual companies remain thin in public reporting, which is typical of expo-stage showcases. What’s been described consistently is the type of product: AI models that read mammograms, cervical smears or oral cavity images and flag suspicious cases for a human doctor to confirm. Some reportedly work offline on a tablet, which matters more in a state like Meghalaya than any cloud-based dashboard ever could.
Why Does AI Cancer Screening Matter More Than the Space Tech Headlines?
Space tech and carbon capture make for better photographs. But AI cancer screening is the one category here that could plausibly touch a patient in a district hospital within the next five years, not the next fifty. India already has a live comparison point: the ongoing HPV vaccination drive has crossed 80 lakh doses nationwide, per government figures reported by ET HealthWorld this week. That’s a decade-long, low-tech public health push — needles, cold chains, school visits — succeeding through sheer administrative grind, not algorithms.
AI cancer screening promises to compress years of specialist shortage into a software layer. A community health worker with a phone-based tool could, in theory, do a first-pass screen that currently requires a gynaecologist or radiologist. For a country where most districts outside metro belts have one oncologist for every few hundred thousand people, that’s not a small claim.
What Does This Look Like Away From the Expo Floor?
I keep coming back to a primary health centre I visited last year in the East Khasi Hills, where the lab technician’s post had been vacant for eight months and the one working ultrasound machine served three blocks. Nobody there was talking about AI. They were talking about diesel for the generator and whether the district hospital in Shillong could see a referral before the month’s OPD quota filled up.
That’s the gap AI cancer screening has to cross. A model trained on scans from AIIMS Delhi or a Bengaluru hospital doesn’t automatically work on equipment, lighting and patient populations in Northeast India, Bastar or rural Odisha. Vendors rarely mention this at expos, because it’s not a pitch problem — it’s a deployment problem, and deployment problems don’t photograph well on a trade-show stage.
How Do the 37 Ventures Break Down by Sector?
| Sector | Approx. Share of Ventures | Health Relevance |
| AI cancer screening & diagnostics | ~13-15 | Direct — breast, cervical, oral cancer detection |
| Space & satellite tech | ~10-12 | Indirect — disaster response, telemedicine links in remote areas |
| Carbon capture & climate tech | ~10-12 | Indirect — air quality, respiratory disease burden |
These figures are approximate, based on how the ventures were grouped at the expo; exact company-by-company breakdowns haven’t been published in full. The pattern still holds — health tech, led by AI cancer screening, was the largest single bucket.
Is There an India-Specific Angle Worth Watching?
Yes, and it isn’t the expo itself. India’s own health ministry has been talking up an “ethical AI vision” for healthcare at forums like the World Health Assembly, alongside its TB elimination push, according to DD News coverage from this week. Officially, India wants to be seen leading on AI cancer screening policy, not just consuming it. Separately, NIMHANS has been named the nodal body for BRICS mental health centres of excellence — a reminder that BRICS health cooperation isn’t limited to one expo, it’s becoming a standing arrangement across several health domains.
The honest test isn’t whether Indian founders can build competitive AI cancer screening tools — several already have working pilots. It’s whether procurement, state health department budgets and last-mile connectivity let those tools reach a PHC in Manipur as readily as a private hospital in Gurugram.
What Happens Next With These 37 Ventures?
Expo showcases are rarely the end of the story; they’re a funding and visibility event. Ventures that impressed BRICS delegations will likely chase pilot contracts with state health departments, insurers, or hospital chains next. For AI cancer screening specifically, the realistic near-term path is partnerships with existing screening programmes — piggybacking on infrastructure that already exists, like the HPV vaccination network, rather than building parallel systems from scratch.
- Pilot deployments in select district hospitals or urban screening camps.
- Validation studies against local patient data, not just international datasets.
- Regulatory clearance through India’s health tech and medical device frameworks.
- Procurement decisions by state governments or insurers, which is usually the slowest step.
FAQ
What is AI cancer screening?
AI cancer screening uses machine learning models to analyse medical images or samples — like mammograms or cervical smears — and flag likely cancer cases for a doctor to review, aiming to speed up early detection.
Which cancers can AI screening currently detect?
Most mature tools target breast, cervical and oral cancers, since these rely on image-based screening that’s easier to automate than blood-based or genomic tests.
Were these BRICS ventures Indian companies?
The 37 ventures came from across BRICS member nations, including India, China, Russia, Brazil, South Africa and newer BRICS partners, not India alone.
Will AI cancer screening reach rural India soon?
Not immediately. Pilots typically start in urban hospitals and screening camps; reaching rural primary health centres depends on funding, connectivity and state-level procurement, which usually takes years.
Is AI cancer screening approved for regular use in Indian hospitals?
Some tools have regulatory clearance and limited hospital deployment, but widespread, government-backed rollout is still in early stages as of 2026.
Conclusion
AI cancer screening deserved the spotlight it got at the BRICS expo — it’s the rare deep-tech pitch with an obvious human payoff. Whether that payoff reaches a patient in Shillong, Silchar or Imphal, though, depends far less on the algorithm and far more on the diesel, staffing and budgets of the health centre nearest to them.